FLUXION BIOSCIENCES launches Isoflux cytation imager for automated CTC analysis

New imager automates imaging and detection of CTCs recovered from the IsoFlux Liquid Biopsy System

September 14 2016

SOUTH SAN FRANCISCO, Calif. -- Fluxion Biosciences, Inc. announced today that it has launched a new imaging system, the IsoFlux Cytation Imager, designed to work exclusively with the IsoFlux Liquid Biopsy System and CTC Enumeration Kit. The IsoFlux Cytation Imager comes pre-configured with all components and software required for automated CTC image acquisition.

Circulating tumor cells (CTCs) disseminate from primary tumors and enter the peripheral bloodstream. Ongoing access to cancer tissue represents one of the most significant challenges in characterizing cancer, and CTCs can alleviate this limitation by providing frequent, minimally-invasive access to cancer tissue via a blood draw. The IsoFlux System uses blood to perform a real-time “liquid biopsy” of the patient’s cancer using the recovered CTCs, which can involve analysis of DNA, RNA, and proteins.

In the research setting, detection of CTCs by protein staining and imaging on an automated microscope is a common workflow, but the cost and complexity of inverted microscopes limit their utility in many labs. The IsoFlux Cytation Imager addresses this limitation by incorporating all components of a high-end microscope into an easy-to-use plate reader-style package. Based on industry-leading imagers from BioTek Instruments, Inc., the IsoFlux Cytation Imager is equipped with an automated stage, autofocus, high-resolution camera, 3-color fluorescence, and the necessary objectives for rapid sample scanning and image capture. Additionally, the imager includes an optional fluorescent channel for detecting protein markers, such as AR-V7 for prostate cancer.

According to Fluxion’s CTO, Dr. Cristian Ionescu-Zanetti, the IsoFlux Cytation Imager will be of great value in clinical research. “This new imager can scan an entire sample in less than 10 minutes, and retains the ability to detect additional protein biomarkers using a 4th fluorescence channel. The automated identification of putative CTCs is another big improvement, reducing the total time required per sample by over 3x as compared to automated microscopes. Use of the IsoFlux Cytation Imager will accelerate clinical studies where CTC enumeration, protein marker detection, and cell-based analysis are important readouts.”

The IsoFlux Cytation Imager (part number 930-0375) is available immediately and can be used with all existing IsoFlux systems and kits without modification. For more information about the IsoFlux System and the new IsoFlux Cytation Imager, visit fluxionbio.com/isoflux.

About Fluxion Biosciences

Fluxion’s IsoFlux CTC Liquid Biopsy System is used in clinical research for early cancer detection and patient monitoring. The IsoFlux System utilizes a novel microfluidic capture technology to isolate and purify circulating tumor cells (CTCs) from a blood sample, enabling cost-effective early detection and ongoing monitoring of actionable mutations via NGS without the need for a traditional biopsy. For more information about Fluxion Biosciences, visit fluxionbio.com.

DOWNLOAD DATA SHEET

 

Fluxion Biosciences Announces Liquid Biopsy Collaboration With University Of Texas Health Science Center

UT Health will utilize Fluxion’s IsoFlux System for development of novel liquid biopsy approaches to improve diagnosis and treatment of cancer from a routine blood draw

SOUTH SAN FRANCISCO, Calif. -- Fluxion Biosciences announced today that it is collaborating with the University of Texas Health Science Center (Houston) to develop novel liquid biopsy approaches to improve the ability to diagnose, monitor, and treat cancer patients. The laboratory of Dr. Robert Amato is utilizing Fluxion’s IsoFlux System (fluxionbio.com/isoflux) to isolate, recover, and analyze rare circulating cancer cells (CTCs) at the molecular level.

Ongoing access to cancer tissue represents one of the most significant challenges in characterizing cancer, and CTCs can alleviate this limitation by providing frequent, minimally-invasive access to cancer tissue via a blood draw. The high efficiency and high purity of CTCs recovered with IsoFlux system allows for the use of highly multiplexed analyses such as next-generation sequencing (NGS) for cancer mutational profiling. This “liquid biopsy” approach allows screening for a broad range of cancer biomarkers that will help guide treatment decisions using an emerging class of precision cancer therapies.

The collaboration with Dr. Amato will initially focus on prostate, kidney, and bladder cancers. One of the world’s leading experts in the treatment of genitourinary cancer, Dr. Amato, full professor and Director of the Division of Oncology at UTHealth Medical School and the Chief of the Division of Oncology at the Memorial Hermann Cancer Center, stated “We have already shown the ability to detect cancer in its early stages, and to measure tumor heterogeneity through single-cell analysis. The use of intact, live cells also offers the ability to measure gene and protein expression, and directly enables the use of mouse models for pharmacodynamic testing. Cancer is a dynamic disease, and the ability to track changes in each patient via a blood sample can allow actionable changes to be detected much earlier. One aim of the collaboration is to identify markers that can help stratify patients requiring more aggressive treatment from those that don’t. This is currently a major challenge in the treatment of prostate cancer.”

About Fluxion Biosciences
Fluxion’s IsoFlux CTC Liquid Biopsy System is used in clinical research for early cancer detection and patient monitoring. The IsoFlux System utilizes a novel microfluidic capture technology to isolate and purify circulating tumor cells (CTCs) from a blood sample, enabling cost-effective early detection and ongoing monitoring of actionable mutations via NGS without the need for a traditional biopsy. For more information about Fluxion Biosciences, visit fluxionbio.com.

About University of Texas Health Science Center at Houston
The University of Texas Health Science Center at Houston (UTHealth) is Houston’s Health University and Texas’ resource for health care education, innovation, scientific discovery and excellence in patient care. UTHealth is home to schools of biomedical informatics, biomedical sciences, dentistry, medicine, nursing and public health. For more information, visit www.uth.edu.

Contact Information
Jeff Jensen
Fluxion Biosciences
Tel: 650-241-4777

Fluxion Launches BioFlux™ Extended Flow Module

Extended Flow can maintain cells under perfusion for up to three weeks

South San Francisco, Calif., March 16, 2016 -- Fluxion Biosciences announced today that it has launched its BioFlux Extended Flow module for live cell analysis. The module consists of a new 6-well plate consumable and interface; it is now available and shipping to customers.

BioFlux provides the ability to emulate physiological flow and shear forces in an in vitro model, while maintaining a convenient well plate format. The system enables a multitude of assays that require precise control of the cellular micro-environment, including control of shear forces, liquid composition, gas, and temperature. BioFlux is widely used in basic research and drug development around the world by hundreds of recognized industry leaders (Pfizer, Amgen, BMS, Merck, Bayer), government labs (NIH, Walter Reed Research Center, VA Medical Center) and leading research institutions (Harvard, UC San Francisco, U. Michigan, U. Pennsylvania, Yale, and Oxford). 

According to Dr. Bryan Haines, Global Product Director, “BioFlux extended flow plates were developed to address a frequent request of our customers: the need to remove flow time limitations from their assays.  The new consumable and 6-well interface accomplish that, while continuing to integrate seamlessly into existing experimental protocols.  Using the BioFlux Quattro Array, 12 experiments can be performed over extended time periods of up to 21 days.”

The Extended Flow Module, including consumables and a 6-well interface, is targeted at applications where longer cell or microbial growth under flow conditions is required. The new consumable extends the flow time significantly, from 31 hours using BioFlux 24-well plates at a shear of 1 dyn/cm2, to 110 hours at the same shear using the new extended flow plates. At low flow rates (0.15 dyn/cm2), BioFlux channels can now be kept under perfusion for up to 21 days.  Long perfusion times are important for applications such as tuberculosis and urinary tract infection research.

“The introduction of the BioFlux Extended Flow Module provides great validation of our new rapid design-to-product development process. In addition to this new plate type, this process is being used to provide a cost-effective path for the production of customer-specific designs and will enable a much faster response time to develop new capabilities for the BioFlux system,” said Cristian Ionescu-Zanetti, CTO of Fluxion. “With its unique capability to mimic conditions in the body, now for much longer periods of time, the Extended Flow Module is a significant advance that provides for a new class of experiments using the BioFlux system.” 

About Fluxion Biosciences

Fluxion Biosciences provides cell analysis tools for use in critical life science, drug discovery, and diagnostic applications. Products include the IsoFlux™ Liquid Biopsy System, the BioFlux™ System for studying cellular interactions and the IonFlux™ System for high throughput patch clamp measurements. Fluxion's systems are designed to replace laborious and difficult assays by providing intuitive, easy-to-use instruments for cell-based analysis. For more information visit www.fluxionbio.com.

Contact
Fluxion Biosciences
BioFlux Marketing & Communications
Ali Yehia, PhD
650-241-4777
ali.yehia@fluxionbio.com

 

Fluxion announced the use of its IonFlux(TM) Automated Patch Clamp System in the discovery of Genentech GNE-0723, a novel drug compound suitable for in vivo characterization.

South San Francisco, Calif. – Genentech’s recent publication “Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design”, details the discovery of a new NMDA receptor PAM with potential implications for neurological disorders such schizophrenia. The drug was developed with the help of unique capabilities provided by the IonFlux HT automated patch clamp (APC) system.

N-methyl-D-asparate receptors (NMDAR) are ubiquitous proteins in the central nervous system thought to be involved in higher cognitive functions and memory formation. Antagonists for NMDAR have been approved for treatment of Alzheimer’s disease, while the receptor’s hypo-function has been associated with schizophrenia. PAMs are molecules capable of enhancing the receptor’s response to its naturally occurring modulator, increasing the receptor’s activity. Genentech published the discovery of a new PAM that is selective to a specific subtype (GluN2A) of the NMDAR subunits. Drug compound GNE-0723 is blood/brain barrier permeable and is ready for in vivo testing.

IonFlux HT was used to evaluate hits from a calcium influx screen and compare the effects of a series of GluN2A-selective PAMs. Due to the toxicity of the receptor to its host cells, incubation with an ion channel blocker is required to preserve cell health. This requires rapid changes of solutions across all patch clamp recording sites, a unique feature of the IonFlux system among other automated electrophysiology platforms.  The authors explain how the IonFlux system was able to measure not only receptor activation, but also deactivation kinetics.  The results were validated by manual patch clamp with a fast perfusion system: “Notably, the deactivation trends observed for each aromatic group in the automated platform matched the trends in the fast perfusion system.“

“IonFlux is the only APC with the sophisticated flow control necessary to run this assay.  Continuous flow coupled with rapid compound switching sets the system apart from other technologies and provides the foundation for performing challenging ligand-gated drug screens such as NMDAR“, explained Dr. Cristian Ionescu-Zanetti, CTO at Fluxion Biosciences.

About Fluxion Biosciences

Fluxion Biosciences manufactures the IonFlux™ automated patch clamp system for ion channel drug discovery. The system deploys a unique in-plate cell attachment, recording and drug delivery system that provides rapid parallel recordings for ligand- and voltage-gated channels and facilitates complicated drug screening assays.  Premier institutions globally use Fluxion’s pioneering platforms, including the IsoFlux liquid biopsy system and the BioFlux cell analysis system in various disease research areas, including cancer, microbiology, and immunology.

FLUXION BIOSCIENCES launches new range of circulating tumor cell (CTC) recovery kits- First launch of commercial kits TARGETING emt cells

New kits add additional markers to improve capture efficiency for a wide variety of circulating cancer cells, including cells that have undergone epithelial-to-mesenchymal transition (EMT)

SOUTH SAN FRANCISCO, Calif. -- Fluxion Biosciences, Inc. announced today that it has launched two new kits for enhanced CTC isolation and recovery that are designed to work exclusively with the IsoFlux Liquid Biopsy system. The new kits include the Enhanced Recovery Kit and the EMT Kit. The Enhanced Recovery kit adds EGFR to the traditional EpCAM antibody, and the EMT kit includes EpCAM, EGFR, and two proprietary mesenchymal phenotype antibodies.

Circulating tumor cells (CTCs) disseminate from primary tumors and enter the peripheral bloodstream. Ongoing access to cancer tissue represents one of the most significant challenges in characterizing cancer, and CTCs can alleviate this limitation by providing frequent, minimally-invasive access to cancer tissue via a blood draw. The IsoFlux System uses blood to perform a real-time “liquid biopsy” of the patient’s cancer using the recovered CTCs. The high efficiency and high purity of the recovered cells allows for the use of highly multiplexed analyses such as next-generation sequencing (NGS) for cancer mutational profiling. Screening for a broad range of cancer biomarkers via NGS will help guide treatment decisions using an emerging class of precision cancer therapies. The introduction of the new CTC kits increases the recovery efficiency of CTCs, further improving the IsoFlux system’s industry-leading sensitivity.

According to Fluxion’s CTO, Dr. Cristian Ionescu-Zanetti, the new kits provide significant gains in cell recovery and open new avenues in clinical research. “It is well known that EpCAM expression levels vary greatly across cancer types and within cancer cell populations.  This can limit the recovery efficiency in very low-expressing cancer types, such as lung and pancreatic cancers. Although the IsoFlux system’s high-sensitivity microfluidic cell recovery performs well on these low expressers when targeting EpCAM, the new kits provide a higher level of performance while enabling recovery of a wider spectrum of cell types. The EMT kit is the first commercially available that targets the mesenchymal cell phenotype for CTCs that have undergone EMT, considered to be a potential contributor to metastasis.”

The Enhanced Recovery Kit (PN 910-0108) and EMT Kit (PN 910-0106) are available immediately and the kits can be used on all existing IsoFlux systems without modification. For more information about the IsoFlux System and the new kits, visit fluxionbio.com/isoflux.

About Fluxion Biosciences

Fluxion’s IsoFlux CTC Liquid Biopsy System is used in clinical research for early cancer detection and patient monitoring. The IsoFlux System utilizes a novel microfluidic capture technology to isolate and purify circulating tumor cells (CTCs) from a blood sample, enabling cost-effective early detection and ongoing monitoring of actionable mutations via NGS without the need for a traditional biopsy. Premier institutions globally use Fluxion’s pioneering platforms, including the IonFlux and BioFlux systems for research and drug discovery, to identify causes and cures for disease. For more information about Fluxion Biosciences, visit fluxionbio.com.

Contacts:

Jeff Jensen
CEO
Fluxion Biosciences
385 Oyster Point Blvd, #3
South San Francisco, CA, 94552

Fluxion Biosciences and Swift Biosciences announce jointly developed next-generation sequencing workflow for somatic mutation detection from liquid biopsy samples

Fluxion Biosciences, Inc. and Swift Biosciences, Inc. announced a new workflow for oncology clinical research designed to detect somatic mutations from a routine blood draw. The jointly-developed workflow utilizes Fluxion’s IsoFlux™ System for circulating tumor cell (CTC) enrichment and Swift’s Accel-Amplicon™ technology for high sensitivity variant detection using low starting inputs.

Read More